Skip to main content
. 2003 Dec 23;101(1):215–220. doi: 10.1073/pnas.0307124101

Fig. 4.

Fig. 4.

Selective down-regulation of SIGN-R1 after injection of antibody. (A) Mice were given 100 μg of control hamster Ig or 22D1 anti-SIGN-R1 antibody (similar results were obtained with rabbit PAb-C13 antibody). One day later, mice were given 100 μg of FITC-dextran i.v., and 1 h later, the spleens were sectioned to assess FITC-dextran uptake (Top) or for staining for hamster Ig, SIGN-R1 (with PAb-C13), and the macrophage receptors MARCO and SER4 (CD169, sialoadhesin). In parallel (Right), samples of spleen tissue were Western-blotted with antibodies to document the selective down-regulation of SIGN-R1. (B) In contrast to A, mice were first given 100 μg of FITC-dextran i.v. and 1 h later 100 μg of control hamster Ig or 22D1 anti-SIGN-R1. One day later, the spleens were examined for the persistence of FITC-dextran in the marginal zone macrophages (green) and the expression of SIGN-R1 (red) by staining with PAb-C13. (C) TKO of SIGN-R1 (green) but not MARCO (red) in macrophages given control Ig or 22D1 hamster monoclonal anti-SIGN-R1 1 day earlier. (Left) The antibody was given i.v. to target macrophages in spleen. (Right) The hamster antibody was given i.p. to target macrophages in mesenteric lymph nodes.